Pharmafile Logo

LGBTQ+

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

Supply chain challenges in 2023

Looking at the supply chain challenges pharmaceutical companies could face

The Path to Patient Centricity

How do we move towards a more patient-centric way of working?

Mednet

- PMLiVE

Astellas to acquire Iveric Bio for approximately $5.9bn

The deal includes the US drugmaker’s lead candidate for geographic atrophy

- PMLiVE

Pfizer’s next-generation pneumococcal vaccine granted FDA approval

The vaccine can help protect against 20 serotypes of the streptococcus pneumoniae bacteria

- PMLiVE

Maintaining the long-term health of the agency sector

How pharma and agency can work together to ensure our ecosystem remains in great health

- PMLiVE

GSK’s RSV vaccine candidate recommended by CHMP for older adults

RSV infections in older adults account for over 270,000 hospitalisations each year in Europe

- PMLiVE

Kite’s CAR-T therapies recommended by NICE for certain blood cancers

The two treatments could benefit up to 600 patients each year in England

- PMLiVE

The greatest show on Earth

Bernie Sanders getting indignant about pharmaceutical companies is must-see TV

- PMLiVE

The CM Group rebrands to OPEN Health

Following its acquisition by OPEN Health in 2022, The CM Group, a US healthcare agency offering a suite of solutions to the biotech and pharma industry, has undergone extensive rebranding...

OPEN Health

- PMLiVE

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in...

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links